https://www.thebodypro.com/article/top-atlas-flair-long-acting-injectable
HIV Treatments in DevelopmentFeatures

ATLAS, FLAIR, and the Upcoming Arrival of Long-Acting Injectable HIV Treatment

#5 in TheBodyPro's Top 10 HIV Clinical Developments of 2019

Long-Acting Antiretrovirals photo illo
Photo illustration: Remedy Health Media; Background and paper tear: iStock

    FLAIR study results: CROI 2019. (2019). "Long-Acting Cabotegravir + Rilpivirine for HIV Maintenance: FLAIR Week 48 Results." http://www.croiconference.org/sessions/long-acting-cabotegravir-rilpivirine-hiv-maintenance-flair-week-48-results

    ATLAS study results: CROI 2019. (2019). "Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: ATLAS Week 48 Results." http://www.croiconference.org/sessions/long-acting-cabotegravir-rilpivirine-maintenance-therapy-atlas-week-48-results

    SWORD study results: The Lancet. (2018). " Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies." https://doi.org/10.1016/S0140-6736(17)33095-7

    David Alain Wohl, M.D.

    David Alain Wohl, M.D.

    David Alain Wohl, M.D., is a professor at the University of North Carolina, site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AETC, and co-director of HIV services for the NC state prison system.